Van Lanschot Kempen Investment Management N.V. Grows Position in Henry Schein, Inc. (NASDAQ:HSIC)

Van Lanschot Kempen Investment Management N.V. increased its position in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 8.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 823,828 shares of the company's stock after purchasing an additional 67,248 shares during the quarter. Van Lanschot Kempen Investment Management N.V. owned approximately 0.66% of Henry Schein worth $57,009,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its position in Henry Schein by 23.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock valued at $52,000 after acquiring an additional 143 shares during the period. Guggenheim Capital LLC boosted its holdings in Henry Schein by 2.5% in the fourth quarter. Guggenheim Capital LLC now owns 6,428 shares of the company's stock worth $445,000 after acquiring an additional 159 shares in the last quarter. CIBC Asset Management Inc grew its stake in shares of Henry Schein by 1.0% in the fourth quarter. CIBC Asset Management Inc now owns 17,849 shares of the company's stock worth $1,235,000 after acquiring an additional 169 shares during the last quarter. Metis Global Partners LLC increased its holdings in shares of Henry Schein by 4.7% during the fourth quarter. Metis Global Partners LLC now owns 4,203 shares of the company's stock valued at $291,000 after acquiring an additional 187 shares in the last quarter. Finally, Central Pacific Bank Trust Division increased its holdings in shares of Henry Schein by 2.0% during the fourth quarter. Central Pacific Bank Trust Division now owns 10,200 shares of the company's stock valued at $706,000 after acquiring an additional 200 shares in the last quarter. 96.62% of the stock is owned by institutional investors.

Henry Schein Stock Performance

Shares of HSIC stock traded down $1.06 during mid-day trading on Friday, reaching $65.17. 736,945 shares of the company's stock traded hands, compared to its average volume of 1,619,867. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The firm has a market capitalization of $7.98 billion, a PE ratio of 26.82, a price-to-earnings-growth ratio of 2.13 and a beta of 0.84. Henry Schein, Inc. has a 12 month low of $60.56 and a 12 month high of $82.49. The firm has a 50 day moving average price of $69.21 and a two-hundred day moving average price of $71.78.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing analysts' consensus estimates of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company had revenue of $3.19 billion during the quarter, compared to analysts' expectations of $3.25 billion. During the same quarter in the previous year, the company earned $0.66 EPS. The business's quarterly revenue was up 5.8% compared to the same quarter last year. On average, research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on HSIC. Jefferies Financial Group upped their target price on shares of Henry Schein from $77.00 to $80.00 and gave the stock a "hold" rating in a research note on Thursday, January 23rd. UBS Group reduced their target price on Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a report on Wednesday, February 26th. Wells Fargo & Company initiated coverage on Henry Schein in a report on Friday, February 14th. They set an "equal weight" rating and a $80.00 price target on the stock. Bank of America raised Henry Schein from an "underperform" rating to a "buy" rating and boosted their target price for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. Finally, StockNews.com downgraded shares of Henry Schein from a "buy" rating to a "hold" rating in a report on Thursday, April 17th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Henry Schein has an average rating of "Moderate Buy" and a consensus target price of $81.10.

Insiders Place Their Bets

In other Henry Schein news, Director Philip A. Laskawy sold 2,604 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the transaction, the director now directly owns 24,805 shares in the company, valued at $1,762,147.20. This represents a 9.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Bradford C. Connett sold 4,036 shares of Henry Schein stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the sale, the chief executive officer now owns 62,688 shares in the company, valued at approximately $4,460,251.20. The trade was a 6.05 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.14% of the company's stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.